Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non–Small-Cell Lung Cancer
Shigehiro Yagishita, Tomohide Tamura(St. Luke's International Hospital), Hiroshi Nokihara(Tokushima University Hospital), Kouya Shiraishi, Takashi Kohno(Gunma University), Koh Furuta(Teikyo University Chiba Medical Center), Tomoko Taniyama, Noboru Yamamoto(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Shinji Nakamichi(Nippon Medical School), Satoru Kitazono(The Cancer Institute Hospital), Yutaka Fujiwara(Aichi Cancer Center), Hidehito Horinouchi(Tokyo National Hospital), Shintaro Kanda(Shinshu University Hospital), Koji Tsuta(Kansai Medical University), Hidenori Mizugaki(Hokkaido University)
International Journal of Radiation Oncology*Biology*Physics
October 13, 2014
Cited by 63
Related Papers
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|365